Download PDF
Aktuelle Neurologie 2007; 34: S6-S10
DOI: 10.1055/s-2007-970907
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Gastrointestinale Störungen bei Morbus Parkinson

Gastrointestinal Disturbances in Patients with Parkinson's DiseaseT.  Müller1 , O.  Götze2 , D.  Woitalla1
  • 1Neurologische Klinik, St. Josef-Hospital, Ruhr-Universität Bochum
  • 2Medizinische Klinik I, St. Josef-Hospital, Ruhr-Universität Bochum
Further Information

Publication History

Publication Date:
04 March 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Schon James Parkinson beschrieb gastrointestinale Dysfunktionen wie vermehrtes Speichelaufkommen, Schluckstörungen und chronische Obstipation. Parkinsonpatienten berichten auch über typische dyspeptische Beschwerden wie Übelkeit, Völlegefühl, frühes Sättigungsgefühl, epigastrische Beschwerden, Erbrechen, Sodbrennen und Meteorismus. Diese können auch von der gastrointestinalen Motilität mit verursacht werden. Eine reduzierte Magenentleerung wird sogar als ein prämotorisches Symptom des Morbus Parkinson diskutiert, da eine Verlangsamung der Magenentleerung auch bei unbehandelten Parkinsonpatienten gezeigt werden konnte und ebenso im Bereich des die intestinale motorische Funktion steuernden enterischen Nervensystems Lewy-Körperchen gehäuft gefunden wurden. Unklar sind die Effekte, die die Therapie mit Levodopa auf die gastrointestinale Motilität ausübt. Zu diskutieren sind neben einem Serotoninmangel, einerseits durch verminderte Aufnahme von Tryptophan oder Abbau von Levodopa zu Dopamin in gastrointestinalen serotonergen neuronalen Zellen. Dies hat vor dem Hintergrund der 5-HT-Rezeptor-gesteuerten Peristaltik einen hypothetischen Einfluss auf die häufige Manifestation einer chronischen Obstipation bei mit Levodopa behandelten Parkinsonpatienten.

Abstract

Even James Parkinson described gastrointestinal symptoms, such as increased saliva in the mouth, dysphagia and chronic constipation. Patients with Parkinson's disease (PD) also complain about typical dyspeptic symptoms such as nausea, fullness, early satiety epigastric pain, vomiting heartburn and meteorism. These symptoms may also result from reduced gastrointestinal motility. Delayed gastric emptying is even discussed as premotor symptom of PD. This was even shown in untreated PD patients and may result from increased appearance of lewy bodies in the enteric nervous system. The impact of levodopa application on gastrointestinal motility is not well studied, levodopa itself delays gastric emptying. However, long-term levodopa application may hypothetically also impact duodenal, jejunal and caecal motility due to decreased tryptophane uptake, which is the metabolic precursor of 5-HT, or the metabolism of levodopa in 5-HT metabolising gastrointestinal neuronal cells. Both may hypothetically cause decreased gastrointestinal 5-HT levels, which may support onset of chronic constipation, since 5-HT stimulates gastrointestinal motility. Constipation is frequent in levodopa treated PD patients.

Schlüsselwörter

Levodopa - Magenentleerung - Obstipation

Key words

levodopa - gastric emptying - constipation

Literatur

  • 1 Parkinson J. An Essay on the Shaking Palsy. London; Sherwood Neely and Jones 1817
    Search in Google Scholar
  • 2 Muller T. Drug treatment of non-motor symptoms in Parkinson's disease.  Expert Opin Pharmacother. 2002;  3 381-388
    CrossrefPubMedSearch in Google Scholar
  • 3 Quigley E M. Gastrointestinal dysfunction in Parkinson's disease.  Semin Neurol. 1996;  16 245-250
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Braak H, Rub U, Gai W P, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.  J Neural Transm. 2003;  110 517-536
    CrossrefPubMedSearch in Google Scholar
  • 5 Braak H, de Vos R A, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.  Neurosci Lett. 2006;  396 67-72
    CrossrefPubMedSearch in Google Scholar
  • 6 Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects.  J Neural Transm. 2004;  111 201-216
    CrossrefPubMedSearch in Google Scholar
  • 7 Goetze O, Wieczorek J, Müller T. et al . Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test.  Neurosci Lett. 2005;  375 170-173
    CrossrefPubMedSearch in Google Scholar
  • 8 Goetze O, Nikodem A B, Wiezcorek J. et al . Predictors of gastric emptying in Parkinson's disease.  Neurogastroenterol Motil. 2006;  18 369-375
    CrossrefPubMedSearch in Google Scholar
  • 9 Hardoff R, Sula M, Tamir A. et al . Gastric emptying time and gastric motility in patients with Parkinson's disease.  Mov Disord. 2001;  16 1041-1047
    CrossrefPubMedSearch in Google Scholar
  • 10 Loeffler D A, Camp D M, Conant S B. Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study.  J Neuroinflammation. 2006;  3 29
    CrossrefPubMedSearch in Google Scholar
  • 11 Sulzer D. alpha-synuclein and cytosolic dopamine: stabilizing a bad situation.  Nat Med. 2001;  7 1280-1282
    PubMedSearch in Google Scholar
  • 12 Kurlan R, Rothfield K P, Woodward W R. et al . Erratic gastric emptying of levodopa may cause „random” fluctuations of parkinsonian mobility.  Neurology. 1988;  38 419-421
    PubMedSearch in Google Scholar
  • 13 Müller T, Erdmann C, Muhlack S. et al . Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.  Mov Disord. 2006;  21 332-336
    CrossrefPubMedSearch in Google Scholar
  • 14 Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.  Expert Opin Pharmacother. 2006;  7 1715-1730
    CrossrefPubMedSearch in Google Scholar
  • 15 Müller T, Erdmann C, Bremen D. et al . Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.  Clin Neuropharmacol. 2006;  29 61-67
    CrossrefPubMedSearch in Google Scholar
  • 16 Woitalla D, Götze O, Kim J I. et al . Levodopa availability improves with progression of Parkinson's disease.  J Neurol. 2006;  253 1221-1226
    PubMedSearch in Google Scholar
  • 17 Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update.  Clin Pharmacokinet. 2006;  45 109-136
    CrossrefPubMedSearch in Google Scholar
  • 18 Müller T, Erdmann C, Muhlack S. et al . Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.  J Neural Transm. 2006;  113 1441-1448
    CrossrefPubMedSearch in Google Scholar
  • 19 Nissinen E, Tuominen R, Perhoniemi V, Kaakkola S. Catechol-O-methyltransferase activity in human and rat small intestine.  Life Sci. 1988;  42 2609-2614
    CrossrefPubMedSearch in Google Scholar
  • 20 Muhlack S, Woitalla D, Welnic J. et al . Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.  Neurosci Lett. 2004;  363 284-287
    CrossrefPubMedSearch in Google Scholar
  • 21 Müller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease [letter].  Lancet. 1999;  354 126-127
    CrossrefPubMedSearch in Google Scholar
  • 22 Gershon M D. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility.  Aliment Pharmacol Ther. 2004;  20, Suppl 7 3-14
    PubMedSearch in Google Scholar
  • 23 Müller T, Muhlack S. Acute levodopa intake and associated cortisol decrease in patients with Parkinson disease.  Clin Neuropharmacol. 2007;  30 101-106
    CrossrefPubMedSearch in Google Scholar
  • 24 Nicholson S L, Brotchie J M. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy.  Eur J Neurol. 2002;  9, Suppl 3 1-6
    PubMedSearch in Google Scholar
  • 25 Wade P R, Cowen T. Neurodegeneration: a key factor in the ageing gut.  Neurogastroenterol Motil. 2004;  16, Suppl 1 19-23
    PubMedSearch in Google Scholar
  • 26 Singaram C, Ashraf W, Gaumnitz E A. et al . Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation.  Lancet. 1995;  346 861-864
    CrossrefPubMedSearch in Google Scholar
  • 27 Takahashi H, Wakabayashi K. The cellular pathology of Parkinson's disease.  Neuropathology. 2001;  21 315-322
    CrossrefPubMedSearch in Google Scholar
  • 28 Wakabayashi K, Takahashi H, Takeda S. et al . Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses.  Acta Neuropathol (Berl). 1988;  76 217-221
    CrossrefPubMedSearch in Google Scholar
  • 29 Wakabayashi K, Takahashi H, Takeda S. et al . Lewy bodies in the enteric nervous system in Parkinson's disease.  Arch Histol Cytol. 1989;  52, Suppl 191-194
    PubMedSearch in Google Scholar
  • 30 Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system.  Acta Neuropathol (Berl). 1990;  79 581-583
    CrossrefPubMedSearch in Google Scholar

Prof. Dr. Thomas Müller

Neurologische Klinik, St. Josef-Hospital, Ruhr-Universität Bochum

Gudrunstraße 56

44791 Bochum

Email: thomas.mueller@ruhr-uni-bochum.de